A Phase II Clinical Study to evaluate the efficacy and safety of NRC-AN-019 in cancer patients failing prior standard therapies

Trial Profile

A Phase II Clinical Study to evaluate the efficacy and safety of NRC-AN-019 in cancer patients failing prior standard therapies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs NRC AN 019 (Primary)
  • Indications Advanced breast cancer; Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Glioma; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Natco Pharma
  • Most Recent Events

    • 04 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top